Patents Assigned to Vascular Biogenics Ltd.
  • Publication number: 20200046852
    Abstract: The invention provides methods of inducing or improving responsiveness to a VEGF antagonist to a subject or a subject population comprising administering an adenovirus comprising a nucleic acid construct comprising a F AS-chimera gene operably linked to an endothelial cell-specific promoter and administering the VEGF antagonist.
    Type: Application
    Filed: July 8, 2019
    Publication date: February 13, 2020
    Applicant: Vascular Biogenics Ltd.
    Inventors: Andrea Rachel LEUBITZ, Naamit SHER, Erez FEIGE, Eyal BREITBART
  • Patent number: 10464957
    Abstract: The present invention is directed to oxidized lipids and pharmaceutical compositions comprising the same. The present invention is also directed to methods of making an oxidized lipid of the invention and to methods of treating or preventing fibrosis or inflammatory diseases or disorders comprising an oxidized lipid of the invention.
    Type: Grant
    Filed: August 16, 2017
    Date of Patent: November 5, 2019
    Assignee: VASCULAR BIOGENICS LTD.
    Inventors: Eti Kovalevski Ishai, Itzhak Mendel, Yaniv Salem, Niva Yacov, Eyal Breitbart
  • Patent number: 10383954
    Abstract: The invention provides methods of inducing or improving responsiveness to a VEGF antagonist to a subject or a subject population comprising administering an adenovirus comprising a nucleic acid construct comprising a F AS-chimera gene operably linked to an endothelial cell-specific promoter and administering the VEGF antagonist.
    Type: Grant
    Filed: May 26, 2017
    Date of Patent: August 20, 2019
    Assignee: Vascular Biogenics Ltd.
    Inventors: Andrea Rachel Leubitz, Naamit Sher, Erez Feige, Eyal Breitbart
  • Patent number: 10369196
    Abstract: Methods of treating a malignant glioma in a subject are disclosed. The methods comprise administering to the subject a therapeutically effective amount of a viral vector comprising: (i) a first polynucleotide sequence encoding a Fas-chimera (Fas-c), said first polynucleotide sequence comprising SEQ ID NOs: 2 and 3; and (ii) a second polynucleotide sequence encoding an endothelial cell-specific promoter or a periendothelial cell-specific promoter.
    Type: Grant
    Filed: March 14, 2013
    Date of Patent: August 6, 2019
    Assignee: Vascular Biogenics Ltd.
    Inventors: Yael Cohen, Livnat Bangio, Andrew J. Brenner, Eyal Breitbart
  • Publication number: 20190054130
    Abstract: The invention provides methods of reducing or decreasing a size of a tumor or eliminating a tumor by inhibiting, decreasing, or reducing neo-vascularization or angiogenesis in a tumor in a patient by administering an adenovirus comprising a nucleic acid construct comprising a FAS-chimera gene operably linked to an endothelial cell-specific promoter. Also provided is a homogeneous population of an adenovirus comprising a FAS-chimera gene operably linked to an endothelial cell-specific promoter and its uses thereof.
    Type: Application
    Filed: July 23, 2018
    Publication date: February 21, 2019
    Applicant: Vascular Biogenics Ltd.
    Inventors: Eyal Breitbart, Andrea Leubitz, Erez Feige, Richard Penson
  • Patent number: 10206936
    Abstract: The present invention is directed to methods of treating or preventing fibrosis comprising an oxidized lipid or pharmaceutical composition comprising the same.
    Type: Grant
    Filed: July 16, 2018
    Date of Patent: February 19, 2019
    Assignee: Vascular Biogenics Ltd.
    Inventors: Itzhak Mendel, Yaniv Salem, Niva Yacov, Eyal Breitbart
  • Patent number: 10022388
    Abstract: The present invention is directed to methods of treating or preventing fibrosis comprising an oxidized lipid or pharmaceutical composition comprising the same.
    Type: Grant
    Filed: May 23, 2017
    Date of Patent: July 17, 2018
    Assignee: Vascular Biogenics Ltd.
    Inventors: Itzhak Mendel, Yaniv Salem, Niva Yacov, Eyal Breitbart
  • Patent number: 9968622
    Abstract: Novel synthetic routes, which are highly applicable for industrial preparation of therapeutically beneficial oxidized phospholipids, are disclosed. Particularly, novel methods for efficiently preparing compounds having a glycerolic backbone and one or more oxidized moieties attached to the glycerolic backbone, which are devoid of column chromatography are disclosed. Further disclosed are novel methods of introducing phosphorus-containing moieties such as phosphate moieties to compounds having glycerolic backbone and intermediates formed thereby. Further disclosed is substantially pure 1-hexadecyl-2-(4?-carboxy)butyl-sn-glycero-3-phosphocholine (CI-201).
    Type: Grant
    Filed: February 13, 2017
    Date of Patent: May 15, 2018
    Assignee: Vascular Biogenics Ltd.
    Inventors: Gideon Halperin, Eti Kovalevski-Ishai
  • Publication number: 20180015183
    Abstract: Disclosed herein are methods and compositions for treating cancer by increasing radiation-induced damage to cancer without increasing radiation-induced side effects by increasing secretory ASMase levels specifically in tumor endothelium, and inducing apoptosis of tumor endothelial cells by treating the tumor with radiation. ASMase levels are increased in tumor endothelium by administration of a recombinant DNA construct comprising a region coding for a functional ASMase linked to particular transcriptional regulatory sequences that confer tissue-specific expression of ASMase.
    Type: Application
    Filed: July 6, 2017
    Publication date: January 18, 2018
    Applicants: MEMORIAL SLOANE-KETTERING CANCER CENTER, Vascular Biogenics Ltd.
    Inventors: Richard N. KOLESNICK, Branka STANCEVIC, Michel SADELAIN, Zvi FUKS, Nira VARDA-BLOOM, Dror HARATS
  • Publication number: 20170354746
    Abstract: The invention provides methods of inducing or improving responsiveness to a VEGF antagonist to a subject or a subject population comprising administering an adenovirus comprising a nucleic acid construct comprising a F AS-chimera gene operably linked to an endothelial cell-specific promoter and administering the VEGF antagonist.
    Type: Application
    Filed: May 26, 2017
    Publication date: December 14, 2017
    Applicant: Vascular Biogenics Ltd.
    Inventors: Andrea Rachel LEUBITZ, Naamit Sher, Erez Feige, Eyal Breitbart
  • Patent number: 9771385
    Abstract: The present invention is directed to oxidized lipids and pharmaceutical compositions comprising the same. The present invention is also directed to methods of making an oxidized lipid of the invention and to methods of treating or preventing fibrosis or inflammatory diseases or disorders comprising an oxidized lipid of the invention.
    Type: Grant
    Filed: November 25, 2015
    Date of Patent: September 26, 2017
    Assignee: Vascular Biogenics Ltd.
    Inventors: Eti Kovalevski Ishai, Itzhak Mendel, Yaniv Salem, Niva Yacov, Eyal Breitbart
  • Patent number: 9682154
    Abstract: The invention provides methods of inducing or improving responsiveness to a VEGF antagonist to a subject or a subject population comprising administering an adenovirus comprising a nucleic acid construct comprising a FAS-chimera gene operably linked to an endothelial cell-specific promoter and administering the VEGF antagonist.
    Type: Grant
    Filed: February 4, 2014
    Date of Patent: June 20, 2017
    Assignee: Vascular Biogenics Ltd.
    Inventors: Andrea Rachel Leubitz, Naamit Sher, Erez Feige, Eyal Breitbart
  • Patent number: 9567605
    Abstract: Anti-angiogenic adenovirus vectors, and therapeutic use thereof are provided, and more particularly, but not exclusively, clinical protocols for treatment of solid tumors in patients with an Ad5-PPE-1-3X-fas-chimera adenovirus vector.
    Type: Grant
    Filed: January 5, 2011
    Date of Patent: February 14, 2017
    Assignee: Vascular Biogenics Ltd.
    Inventors: Yael Cohen, Naamit Sher, Erez Feige, Livnat Bangio, Eyal Breitbart
  • Patent number: 9403887
    Abstract: An isolated polynucleotide is disclosed comprising a nucleic acid sequence encoding a polypeptide having an amino acid sequence of HIF-1alpha, the polypeptide being stably expressed and constitutively active. Isolated polypeptides encoded by same are also disclosed and uses thereof.
    Type: Grant
    Filed: September 24, 2014
    Date of Patent: August 2, 2016
    Assignee: Vascular Biogenics Ltd.
    Inventors: Eyal Breitbart, Livnat Bangio, Reshef Tal
  • Publication number: 20160143968
    Abstract: The invention provides methods of reducing or decreasing a size of a tumor or eliminating a tumor by inhibiting, decreasing, or reducing neo-vascularization or angiogenesis in a tumor in a patient by administering an adenovirus comprising a nucleic acid construct comprising a FAS-chimera gene operably linked to an endothelial cell-specific promoter. Also provided is a homogeneous population of an adenovirus comprising a FAS-chimera gene operably linked to an endothelial cell-specific promoter and its uses thereof.
    Type: Application
    Filed: November 23, 2015
    Publication date: May 26, 2016
    Applicant: Vascular Biogenics Ltd.
    Inventors: Eyal BREITBART, Andrea Leubitz, Erez Feige
  • Publication number: 20160121001
    Abstract: The invention provides methods of inducing or improving responsiveness to a VEGF antagonist to a subject or a subject population comprising administering an adenovirus comprising a nucleic acid construct comprising a FAS-chimera gene operably linked to an endothelial cell-specific promoter and administering the VEGF antagonist.
    Type: Application
    Filed: February 4, 2014
    Publication date: May 5, 2016
    Applicant: Vascular Biogenics Ltd.
    Inventors: Andrea Rachel LEUBITZ, Naamit SHER, Erez FEIGE, Eyal BREITBART
  • Patent number: 9254297
    Abstract: The current disclosure provides pharmaceutical compositions containing an oxidized phospholipid, such as 1-hexadecyl-2-(4?-carboxybutyl)-glycero-3-phosphocholine (VB-201) and a thermosoftening carrier, e.g., a poloxamer. The pharmaceutical compositions may further comprise an anti-adherent agent, such as talc and/or a thixotropic agent. The current disclosure further provides processes for preparing the pharmaceutical compositions. The disclosure further provides capsules containing the pharmaceutical compositions. Uses of such pharmaceutical compositions and capsules in treating inflammatory disorders are also disclosed.
    Type: Grant
    Filed: March 11, 2013
    Date of Patent: February 9, 2016
    Assignee: Vascular Biogenics Ltd.
    Inventors: Naamit Sher, Victor M. Young, Alyn McNaughton, Massoud Bakhshaee, Ian Robert Wilding
  • Patent number: 9206206
    Abstract: Novel oxidized lipids are provided herein, as well as methods for producing same, and uses thereof in treating or preventing an inflammation associated with endogenous oxidized lipids and related conditions.
    Type: Grant
    Filed: November 5, 2009
    Date of Patent: December 8, 2015
    Assignee: Vascular Biogenics Ltd.
    Inventors: Eti Kovalevski-Ishai, Zeev Ziniuk, Gideon Halperin, Itzhak Mendel, Erez Feige, Niva Yacov, Eyal Breitbart
  • Patent number: 9200056
    Abstract: The invention provides methods of reducing or decreasing a size of a tumor or eliminating a tumor or inhibiting, decreasing, or reducing neo-vascularization or angiogenesis in a tumor in a patient by administering an adenovirus comprising a nucleic acid construct comprising a FAS-chimera gene operably linked to an endothelial cell-specific promoter. Also provided is a homogeneous population of an adenovirus comprising a FAS-chimera gene operably linked to an endothelial cell-specific promoter and its uses thereof.
    Type: Grant
    Filed: October 29, 2014
    Date of Patent: December 1, 2015
    Assignee: Vascular Biogenics Ltd.
    Inventors: Eyal Breitbart, Andrea Leubitz, Erez Feige, Richard Penson
  • Patent number: 9006217
    Abstract: Novel synthetic routes, which are highly applicable for industrial preparation of therapeutically beneficial oxidized phospholipids, are disclosed. Particularly, novel methods for efficiently preparing compounds having a glycerolic backbone and one or more oxidized moieties attached to the glycerolic backbone, which are devoid of column chromatography are disclosed. Further disclosed are novel methods of introducing phosphorus-containing moieties such as phosphate moieties to compounds having glycerolic backbone and intermediates formed thereby. Further disclosed is substantially pure 1-hexadecyl-2-(4?-carboxy)butyl-sn-glycero-3-phosphocholine (CI-201).
    Type: Grant
    Filed: March 15, 2013
    Date of Patent: April 14, 2015
    Assignee: Vascular Biogenics Ltd.
    Inventors: Gideon Halperin, Eti Kovalevski-Ishai